Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Hepatitis C Screening in Intravenuos Drug Users in Golpayegan, Isfahan Through Community Announcement: Pilot Study



Ataei B1 ; Meshkati M2 ; Karimi A3 ; Yaran M4 ; Kassaian N4 ; Nokhodian Z4 ; Shoaei P4 ; Adibi P5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Infectious Diseases, School of Medicine and Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. AIDS, Hepatitis and Sexual Transmitted Diseases Expert, Isfahan University of Medical Sciences Health Center, Isfahan, Iran
  3. 3. Disease Control Unit, Golpayegan ince Health Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Department of Gastroenterology, School of Medicine and Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2011

Abstract

Background: Intravenous drug abuse is a worldwide problem with side effects as hepatitis C. Hepattis C infection, which has severe complications like cirrosis and hepatocellular carcinoma, is a tragedy for communities; so, screening it in intravenous drug abusers has a lot of benefits. According to lack of a community based study in Isfahan, Iran, this pilot study carried out in Golpayegan city in Isfahan Province. Methods: In a cross sectional pilot study, hepatitis C in intravenous drug abusers population in Golpaygan, Isfahan was screened by community annaouncement method. After co-opperation with managers, administrative stafs and all of the stakeholders, the study population was invited to refference laboratories where blood samples were chpsen and tested for anti-HCV-Ab. The results were sent privately and patients were invited to participate in educational and treatment procedure. Finding: From 136 persons participated voluntarily, 28 were anti-HCV-Ab positive (19.8%). Conclusion: In this pilot study, 85% of estimated population was participated that is excellent experience for larger studies.
Related Docs
View other Related Docs
1. Positive Hepatitis C Virus Antibody in Cases With History of Intravenous Drug Abuse Via Community Announcement: A Useful Experience, Journal of Isfahan Medical School (2011)
2. Hepatitis C in Intravenous Drug Users: Seroprevalence and Risk Factors, Journal of Isfahan Medical School (2011)
3. Hepatitis C Screening in Isfahan Drop in Centers: An Experience Description, Journal of Isfahan Medical School (2011)
4. Identification of Patients With Hepatitis C Virus Infection in Persons With Background of Intravenous Drug Use: The First Community Announcementbased Study From Iran, International Journal of Preventive Medicine (2012)
5. Hepatitis C Among Intravenous Drug Users in Isfahan, Iran: A Study of Seroprevalence and Risk Factors, International Journal of Preventive Medicine (2012)
6. The Experience of Hepatitis C Screening Among Prison Inmates With Drug Injection History, Journal of Isfahan Medical School (2011)
7. Hepatitis C Virus in Iran: Epidemiology of an Emerging Infection, Archives of Iranian Medicine (2005)
8. Hepatitis C Seroprevalence Among Intravenous Drug Users in Tehran, Journal of Research in Medical Sciences (2008)
Experts (# of related papers)
View all Related Experts
Behrooz Ataei (36)
Nazila Kassaian (26)
Other Related Docs
9. Hepatitis C Virus Seroprevalence and Associated Risk Factors Among Male Drug Injectors in Kermanshah, Iran, Hepatitis Monthly (2017)
10. Hepatitis C in Correctional Centers: A Useful Experience, Journal of Isfahan Medical School (2011)
11. Hepatitis C Screening in Intravenous Drug Users Under Treatment With Methadone: An Action Reserch Study, Journal of Isfahan Medical School (2011)
12. High Risky Behaviors Among Intravenous Drug Users in Isfahan, Iran: A Study for Hepatitis C Harm Reduction Programs, International Journal of Preventive Medicine (2012)
13. The Assessment of Hepatitis B Seroprevalence in Persons With Intravenous Drug Use History in the Isfahan Province: Community-Based Study, Journal of Research in Medical Sciences (2014)
14. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline, Hepatitis Monthly (2016)
15. Seroprevalence of Hepatitis a in Patients With Chronic Hepatitis C in Isfahan Province, International Journal of Preventive Medicine (2012)
16. Assessment of Hepatitis C Risk Factors in Center of Iran: A Case-Control Study, Journal of Research in Medical Sciences (2018)
17. Hepatitis C Virus and Associated Risk Factors Among Prison Inmates With History of Drug Injection in Isfahan, Iran, International Journal of Preventive Medicine (2012)
18. Relative Frequency of Early Virologic Response to Treatment With a Combination of Conventional Interferon and Ribavirin in Patients With Chronic Hepatitis C, Journal of Isfahan Medical School (2012)
19. Hepatitis C in Patients With Multi Blood Transfusion, Journal of Isfahan Medical School (2011)
20. Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial, Clinical Infectious Diseases (2020)
21. Seroprevalence of Hepatitis B Markers Among Incarcerated Intravenous Drug Users, Journal of Research in Medical Sciences (2014)
22. Seroprevalence of Hepatitis C Infection Among Laboratory Health Care Workers in Isfahan, Iran, International Journal of Preventive Medicine (2012)
23. Hepatitis C Virus Infection in Patients With Hemophilia in Isfahan, Iran, International Journal of Preventive Medicine (2012)
24. The Association of Non-O Blood Group and Severity of Liver Fibrosis in Patients With Chronic Hepatitis C Infection, Journal of Research in Medical Sciences (2012)
25. Correlation Between Il-28 Polymorphism and Spontaneous Clearance in Hcv Patients: Systematic Review and Meta-Analysis, Archives of Virology (2021)
26. Comparison of the Prevalence and Risk Factors of Hepatitis a in 10 to 18-Year-Old Adolescents of Sixteen Iranian Provinces: The Caspian-Iii Study, Hepatitis Monthly (2016)
27. Comparing the Effectiveness of a Short-Term Double-Dose Hepatitis B Vaccination Schedule With the Standard 3-Dose Schedule: A Randomized Clinical Trial, Tehran University Medical Journal (2011)
28. Screening for Hepatocellular Carcinoma in Chronic Carriers of Hepatitis B and C in Markazi Province, Iran, Hepatitis Monthly (2007)
29. Seroprevalence of Hbv, Hcv and Hiv Infection Among Intravenous Drug Users in Shahr-E-Kord, Islamic Republic of Iran, Eastern Mediterranean Health Journal (2008)
30. Review of Hepatocellular Carcinoma and Liver Disease Prevalence, New Emirates Medical Journal (2024)
31. Prevalence and Risk Factors for Hepatitis B and Hepatitis C Exposure in Iranian Prisoners: A National Study in 2016, Hepatitis Monthly (2019)
32. Surveillance System for Hepatitis C Infection: A Practical Approach, International Journal of Preventive Medicine (2012)
33. The Combination of Sofosbuvir and Daclatasvir Is Effective and Safe in Treating Patients With Hepatitis C and Severe Renal Impairment, Journal of Gastroenterology and Hepatology (Australia) (2020)
34. Analysis of the Related Factors in Hepatitis C Virus Infection Among Hemophilic Patients in Isfahan, Iran, Hepatitis Monthly (2007)
35. Prevalence of Hbv and Hcv Infections and Associated Risk Factors in Addict Prisoners, Iranian Journal of Public Health (2006)
36. Hepatitis B and C Among Patients Infected With Human Immunodeficiency Virus in Isfahan, Iran: Seroprevalence and Associated Factors, Hepatitis Monthly (2010)
37. Seroepidemiology of Hepatitis a Virus Infections in Over 6-Years Population in Isfahan–Iran: A Community-Based Study, Journal of Isfahan Medical School (2007)
38. Seroprevalence of Hepatitis B Virus Infection and Hepatitis B Surface Antibody Status Among Laboratory Health Care Workers in Isfahan, Iran, Asian Journal of Transfusion Science (2015)
39. Prevalence and Risk Factors of Hepatitis B Infection in Injection Drug Users, Tehran (2001-2002), Hepatitis Monthly (2008)
40. Efficacy of Interferon Alpha-2B With or Without Ribavirin in Thalassemia Major Patients With Chronic Hepatitis C Virus Infection: A Randomized, Double Blind, Controlled, Parallel Group Trial, Journal of Research in Medical Sciences (2010)
41. Seroprevalence of Hepatitis a Virus in Patients With Chronic Hepatitis B or C in Isfahan Province, Iran, Journal of Isfahan Medical School (2012)
42. Risk Prison and Hepatitis B Virus Infection Among Inmates With History of Drug Injection in Isfahan, Iran, The Scientific World Journal (2013)
43. Prevalence of Hiv/Hcv/Hbv Infections and Drug-Related Risk Behaviours Amongst Idus Recruited Through Peer-Driven Sampling in Iran, International Journal of Drug Policy (2010)
44. Prevalence of Hepatitis B Virus Infection in Isfahan Province, International Journal of Preventive Medicine (2014)
45. Prevalence and Risk Factors of Hiv, Syphilis, Hepatitis B and C Among Female Prisoners in Isfahan, Iran, Hepatitis Monthly (2012)
46. Comparison of Liver Biopsy With Hepascore in Patients With Hepatitis C-Genotype 1, Journal of Isfahan Medical School (2011)
47. Efficacy of Triple Therapy With Interferon Alpha-2B, Ribavirin and Amantadine in the Treatment of Naive Patients With Chronic Hepatitis C, Journal of Research in Medical Sciences (2007)
48. Occult Hepatitis B Virus (Hbv) Infection: A Global Challenge for Medicine, Clinical Laboratory (2012)
49. Hepatitis a Seropositivity Among Newly Admitted Medical Students of Isfahan, Kermanshah, and Hamedan: A Seroprevalence Study, Journal of Research in Medical Sciences (2014)
50. Hepatitis C Virus Genotype Frequency in Isfahan Province of Iran: A Descriptive Cross-Sectional Study, Virology Journal (2010)